|
|
| American Recovery and Reinvestment Act of 2009 |
|
 |
|
|
|
|
|
|
|
|
|
NIH Challenge Grants in Health and Science Research
(RFA-OD-09-003)
|
|
|
| |
OD - Office of Science Policy (OSP)
|
|
|
| |
On February 17, 2009, President Obama signed the American Recovery & Reinvestment Act of 2009 (Recovery Act). The Recovery Act, Pub. L. No. 111-5, included new funds for NIH for Fiscal Years 2009 and 2010. The NIH has designated at least $200 million in FYs 2009 - 2010 for a new initiative called the NIH Challenge Grants in Health and Science Research.
|
|
|
| |
This new program will support research on topic areas that address specific scientific and health research challenges in biomedical and behavioral research that would benefit from significant 2-year jumpstart funds.
|
|
|
| |
The NIH has identified 15 Challenge Areas that focus on specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that would benefit from an influx of funds to quickly advance the area in significant ways. Each NIH Institute, Center, and Office has selected specific
Challenge Topics within the broad Challenge Areas
related to its mission. Within the Bioethics Challenge Area, five of the high-priority topics have been identified by the Office of the Director (OD). Each of these Bioethics Challenge Topics relates to one or more of the other Challenge Areas. This approach reflects NIH's commitment to support the exploration of ethical issues concurrent with the advancement of research. Addressing ethical issues associated with the Challenge Areas will help realize their scientific and public health promise.
|
|
|
| |
The application due date is April 27, 2009.
|
|
| |
|
|
|
|
Broad Challenge Areas and Specific Challenge Topics
|
|
|
|
| |
Note: |
Those marked with an asterisk (*) are the highest priority topics; however, applicants may apply to any of the topics.
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
For OD, the
Bioethics (02)
Challenge Topics are:
|
|
| |
|
| |
02-OD(OSP)-101* Unique Ethical Issues Posed by Emerging Technologies.
Advances in biotechnology and biomedical science raise novel ethical, legal, and social issues. Research in this area is needed to understand the unique ethical concerns related to emerging technologies (e.g. biotechnology, tissue engineering, nanomedicine, and synthetic biology). These include issues such as dual use research, privacy, safety, intellectual property, commercialization and conflict of interest, among others. Research is also needed to assess how these novel issues are addressed under current oversight and regulatory structures and identify where there may be gaps and/or need for revised or new oversight approaches. Contact: Abigail Rives, NIH Office of Biotechnology Activities, 301-594-1976, rivesa@od.nih.gov.
|
|
| |
|
| |
02-OD(OSP)-102* Ethical Issues in Health Disparities and Access to Participation in Research.
Research is needed to assess the under-representation in biomedical and clinical research of U.S. minority populations, underserved populations, and populations who may be vulnerable to coercion or undue influence, to identify barriers to participation in research and to develop approaches for overcoming them. Additionally, studies are needed to assess the impact and ethical considerations of conducting biomedical and clinical research internationally in resource-limited countries. Contact: Abigail Rives, NIH Office of Biotechnology Activities, 301-594-1976, rivesa@od.nih.gov.
|
|
| |
|
| |
02-OD(OSP)-103* Ethical Issues Associated with Electronic Sharing of Health Information.
The development of an electronic health information infrastructure and the sharing of health information for patient care and research offers enormous promise to improve health care and promote scientific advances. However, the broad sharing of such data raises numerous ethical issues that may benefit from additional studies (e.g. those related to privacy and confidentiality). Examples include studies to assess risks associated with health information technology and the broad sharing of health information for research, and novel approaches for mitigating them. Examination could also include analysis of current oversight paradigms and suggestions for enhancements, as well as assessments of how privacy risks may change in the future. Contact: Abigail Rives, NIH Office of Biotechnology Activities, 301-594-1976, rivesa@od.nih.gov.
|
|
| |
|
| |
02-OD(OSP)-104* Ethical Issues in the Translation of Genetic Knowledge to Clinical Practice.
Genetics and genomics have great promise for the development of personalized medicine, yet the ethical, legal and social implications of both the research and application of genetic and genomic knowledge and technology are far reaching. Studies are needed to better understand the factors that influence the translation of genetic information to improved human health and the associated ethical issues. Examples of studies include those to address ethical issues related to broad sharing and use of new genetic information and technologies for research to improve human health, human subjects protection in genetic and genomic research, the identifiability of genetic/genomic information and how our understanding of identifiability is evolving, return of research results and incidental findings to subjects, alternative models of informed consent for broad data sharing for research, and the impact of intellectual property (IP) issues on development of new technologies. Contact: Abigail Rives, NIH Office of Biotechnology Activities, 301-594-1976, rivesa@od.nih.gov.
|
|
| |
|
| |
02-OD(OSP)-105* Ethical Issues Raised by the Blurring between Treatment and Research.
The distinction between clinical practice and research is growing less clear, a trend that may be more pronounced with respect to genetic information and medical records research. Studies are needed to better understand the ethical issues associated with this trend. Examples of studies include those to identify how this blurring in roles affects traditional human subjects protections, including, for example, essential practices such as informed consent, conceptions of the doctor/patient and investigator/subject relationship, and privacy protections. Contact: Abigail Rives, NIH Office of Biotechnology Activities, 301-594-1976, rivesa@od.nih.gov.
|
|
| |
|
| |
For general information about OD's Bioethics Challenge Grants, contact:
Abigail Rives
Health Science Policy Analyst
Office of Biotechnology Activities
Office of Science Policy
Office of the Director
National Institutes of Health
301-594-1976
rivesa@od.nih.gov.
|
|
| |
|
| |
For IC-specific, programmatic questions, please contact one of the following individuals:
|
|
|
| |
For 02-OD(OSP)-101: Unique Ethical Issues Posed by Emerging Technologies.
|
|
|
| |
NCI: Jerry Lee, 301-594-0255, leejerry@mail.nih.gov
NHLBI: Gail Weinmann, 301-435-0233, weinmanng@nhlbi.nih.gov
NHGRI: Joy Boyer, 301-402-4997, jb40m@nih.gov
NIA: Robin Barr, 301-402-7715, BarrR@mail.nih.gov
NIAID: Liza Dawson, 301-496-6179, dawsonl@niaid.nih.gov
NIAMS: Joan McGowan, 301-594-5055, NIAMShelp-NIHChallengeGrants@mail.nih.gov
NIBIB: Belinda Seto, 301-451-6768, setob@mail.nih.gov
NICHD: James Hanson, 301-496-8535, hansonj@mail.nih.gov
NIDCR: Nadya Lumelsky, 301-594-7703, Nadya.Lumelsky@nih.gov
NIDDK: Oliver Blondel, 301-451-7334, blondelol@niddk.nih.gov
NIEHS: David Balshaw, 919-541-2448, Balshaw@niehs.nih.gov
NIGMS: Richard Anderson, 301-594-0943, vandersor@nigms.nih.gov
NIMH: Jean Noronha, 301-443-3367, jnoronha@mail.nih.gov
NINDS: Joe Pancrazio, 301-496-1447, jp439m@nih.gov
NINR: Josephine Boyington, 301-594-2542, boyingtonje@mail.nih.gov
NCCAM: Jack Killen, 301-594-7103, killenj@mail.nih.gov
|
|
|
| |
For 02-OD(OSP)-102: Ethical Issues in Health Disparities and Access to Participation in Research.
|
|
|
| |
NCI: Alexis Bakos, 301-443-0542, bakosa@mail.nih.gov
NCI: Carmen Moten, 301-496-8589, cmoten@mail.nih.gov
NCI: Shobha Srinivasan, 301-435-6614, Sriniva2@mail.nih.gov
NHLBI: Gail Weinmann, 301-435-0233, weinmanng@nhlbi.nih.gov
NHGRI: Jean McEwen, 301 402-7997, jm552n@mail.gov.nih
NIA: Robin Barr, 301-402-7715, BarrR@mail.nih.gov
NIAID: Liza Dawson, 301-496-6179, dawsonl@niaid.nih.gov
NICHD: Regina James, 301-435-2692, rjames@mail.nih.gov
NIDCR: Ruth Nowjack-Raymer, 301-594-5394, nowjackr@nidcr.nih.gov
NIDCR: Melissa Riddle, 301-451-3888, riddleme@mail.nih.gov
NIDDK: Rebekah Rasooly, 301-594-6007, RasoolyR@EXTRA.NIDDK.NIH.GOV
NIEHS: Liam O'Fallon, 919-541-7733, Ofallon@niehs.nih.gov
NIMH: Jean Noronha, 301-443-3367, jnoronha@mail.nih.gov
NINDS: Salina Waddy, 301-496-3102, Salina.Waddy@nih.gov
NINR: Josephine Boyington, 301-594-2542, boyingtonje@mail.nih.gov
FIC: Barbara Sina, 301-402-9467, sinab@mail.nih.gov
NCMHD: Joyce Hunter, 301-402-1366, hunterj@mail.nih.gov
|
|
|
| |
For 02-OD(OSP)-103: Ethical Issues Associated with Electronic Sharing of Health Information.
|
|
|
| |
NCI: Chris Kinsinger, 301-436-1550, kinsingc@mail.nih.gov
NCI: Marsha Reichman, 301-534-7032, reichmam@mail.nih.gov
NHLBI: Gail Weinmann, 301-435-0233, weinmanng@nhlbi.nih.gov
NHGRI: Jean McEwen, 301 402-7997, jm552n@mail.gov.nih
NIA: Robin Barr, 301-402-7715, BarrR@mail.nih.gov
NIAAA: Patricia Powell, 301-443-5106, ppowell@mail.nih.gov
NIAID: Liza Dawson, 301-496-6179, dawsonl@niaid.nih.gov
NIBIB: Belinda Seto, 301-451-6768, setob@mail.nih.gov
NIDCR: Ruth Nowjack-Raymer, 301-594-5394, nowjackr@nidcr.nih.gov
NIDCR: Melissa Riddle, 301-451-3888, riddleme@mail.nih.gov
NIDDK: Christine Hunter, 301-594-4728, hunterchristine@niddk.nih.gov
NIMH: Jean Noronha, 301-443-3367, jnoronha@mail.nih.gov
NINR: Josephine Boyington, 301-594-2542, boyingtonje@mail.nih.gov
NLM: Valerie Florance, 301-594-4882, florancev@mail.nih.gov
NCCAM: Jack Killen, 301-594-7103, killenj@mail.nih.gov
NCRR: Louise Ramm, 301-435-0879, ramml@mail.nih.gov
|
|
|
| |
For 02-OD(OSP)-104: Ethical Issues in the Translation of Genetic Knowledge to Clinical Practice.
|
|
|
| |
NCI: Mehdi Mesri, 301-496-1550, mesrim@mail.nih.gov
NCI: Leah Sansbury, 301-435-4910, sansburl@mail.nih.gov
NEI: Grace Shen, 301-451-2020, sheng@mail.nih.gov
NHLBI: Gail Weinmann, 301-435-0233, weinmanng@nhlbi.nih.gov
NHGRI: Elizabeth Thomson, 301-402-4997, et22s@nih.gov
NIA: Robin Barr, 301-402-7715, BarrR@mail.nih.gov
NIAID: Liza Dawson, 301-496-6179, dawsonl@niaid.nih.gov
NIAMS: Joan McGowan, 301-594-5055, NIAMShelp-NIHChallengeGrants@mail.nih.gov
NICHD: James Hanson, 301-496-8535, hansonj@mail.nih.gov
NIDCR: Emily Harris, 301-594-4846, harrisel@nidcr.nih.gov
NIDDK: Rebekah Rasooly, 301-594-6007, RasoolyR@EXTRA.NIDDK.NIH.GOV
NIEHS: Kim McAllister, 919-541-4528, Mcallis2@niehs.nih.gov
NIMH: Jean Noronha, 301-443-3367, jnoronha@mail.nih.gov
NINDS: Danilo Tagle, 301-446-5748, dt39y@nih.gov
NINR: Josephine Boyington, 301-594-2542, boyingtonje@mail.nih.gov
|
|
|
| |
For 02-OD(OSP)-105: Ethical Issues Raised by the Blurring between Treatment and Research.
|
|
|
| |
NCI: Paul Han, 301-594-6642, hanp@mail.nih.gov
NHLBI: Gail Weinmann, 301-435-0233, weinmanng@nhlbi.nih.gov
NHGRI: Elizabeth Thomson, 301-402-4997, et22s@nih.gov
NIA: Robin Barr, 301-402-7715, BarrR@mail.nih.gov
NIAID: Liza Dawson, 301-496-6179, dawsonl@niaid.nih.gov
NIDCR: Jane Atkinson, 301-435-7908, Jane.Atkinson@nih.gov
NIDDK: Rebekah Rasooly, 301-594-6007, RasoolyR@EXTRA.NIDDK.NIH.GOV
NIEHS: Kim Gray, 919-541-0293, Gray6@niehs.nih.gov
NIMH: Jean Noronha, 301-443-3367, jnoronha@mail.nih.gov
NINDS: Brandy Fureman, 301-496-9135, bf103s@nih.gov
NINR: Josephine Boyington, 301-594-2542, boyingtonje@mail.nih.gov
FIC: Barbara Sina, 301-402-9467, sinab@mail.nih.gov
NCCAM: Jack Killen, 301-594-7103, killenj@mail.nih.gov
|
|
Top of Page |
| |
|
|
|
